Abstract:STUDY QUESTION Do dehydroepiandrosterone (DHEA)-treated rats with polycystic ovary syndrome (PCOS) demonstrate a high level of fibrosis in ovarian and uterine tissues? SUMMARY ANSWER DHEA induces ovarian and uterine hyperfibrosis in rats, probably involving a transforming growth factor-β (TGF-β)-dependent mechanism. WHAT IS KNOWN ALREADY Chronic inflammation is the typical cause of fibrosis and is involved in the pathophysiological process of PCOS. Patients with PCOS are reported to have a higher serum level of TGF-β, a well-characterized key pro-fibrotic factor. Fibrillin-3, a protein capable of interacting with TGF-β, has been reported to be partially responsible for the fetal origin of PCOS. STUDY DESIGN, SIZE, DURATION Female Sprague-Dawley rats were treated with a vehicle control or DHEA for 35 days, with subsequent analyses of changes in morphology and gene expression in ovarian and uterine tissues. Rescue groups treated with metformin or simvastatin and their corresponding controls were also analyzed. A total of 80 rats were included. PARTICIPANTS/MATERIALS, SETTING, METHODS The PCOS model was induced by daily administration of DHEA s.c. to 3-week-old female rats, and the rescue groups were injected daily with either metformin or simvastatin in addition to DHEA. Serum steroid hormone levels were measured by enzyme-linked immunosorbent assay. Samples were stained with hematoxylin and eosin for histological morphology, and Sirius Red and immunohistochemistry for revealing collagens. The expression of fibrosis-related genes was analyzed both at mRNA (real-time RT-PCR) and protein (western blot) levels. MAIN RESULTS AND THE ROLE OF CHANCE DHEA-induced rats with PCOS exhibited significantly higher levels of fibrosis (collagen IV) in both ovarian and uterine tissues. In ovarian tissue, the expression of connective tissue growth factor (CTGF) increased following DHEA treatment at both mRNA and protein levels (P < 0.05, P < 0.001 versus controls, respectively). Similar results versus controls were obtained at a protein level for TGF-β (P < 0.01) and mRNA level for fibronectin (P < 0.05) and angiotensin-II (P < 0.05). Likewise, in uterine tissue, the protein levels of both CTGF and TGF-β were higher than controls following DHEA treatment (P < 0.05). Treatment with either metformin or simvastatin attenuated the fibrosis progression induced by DHEA exposure, as evidenced by a reduction of TGF-β, plus CTGF or not, in both ovarian and uterine tissues. LIMITATIONS, REASONS FOR CAUTION The particular mechanism involved in the DHEA-induced fibrosis was not fully revealed. WIDER IMPLICATIONS OF THE FINDINGS Ovarian and uterine hyperfibrosis may occur in patients with PCOS and result in anovulation or other PCOS-related phenotypes. Anti-fibrotic therapy, for example metformin treatment, may be beneficial for patients with PCOS. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by the National Natural Science Foundation of China (81170541) and the Natural Basic Research Program of China (973 program 2010CB945103). The authors declare no conflicts of interest.

Induction of Rat Polycystic Ovary Syndrome by Dehydroepiandrosterone

Dehydroepiandrosterone with a high-fat diet treatment at inducing polycystic ovary syndrome in rat model

Dehydroepiandrosterone-induced polycystic ovary syndrome mouse model requires continous treatments to maintain reproductive phenotypes

Expression of PPAR-γ in Adipose Tissue of Rats with Polycystic Ovary Syndrome Induced by DHEA.

Reproductive Phenotypes of Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mouse Model Cannot be Maintained after Treatment Withdrawal

Cytoarchitectural differences in reproductive organs of some polycystic ovary-like induced animal models

A Rat Polycystic Ovary Model Established by Combined use of Insulin and Human Chorionic Gonadotrophin

Differences of Manifestation and Gut Microbiota Composition Between Different Polycystic Ovary Syndrome Rat Models

Effects of dodder total flavone on polycystic ovary syndrome rat models induced by DHEA combined HCG

Depression-Like Behavior in a Dehydroepiandrosterone-Induced Mouse Model of Polycystic Ovary Syndrome

Comparative Analysis of Two Methods for Polycystic Ovary Syndrome Model Making in Rats

Dehydroepiandrosterone Induces Ovarian and Uterine Hyperfibrosis in Female Rats.

High-Fat Diet Induces Significant Metabolic Disorders in a Mouse Model of Polycystic Ovary Syndrome1

Assessment of Growth and Metabolism Characteristics in Offspring of Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Adults

The Improvement Effect of D-Chiro-Inositol and Ecklonia Cava K. in the Rat Model of Polycystic Ovarian Syndrome.

Polycystic ovarian syndrome is accompanied by repression of gene signatures associated with biosynthesis and metabolism of steroids, cholesterol and lipids

CHINESE HERBAL MEDICINE ALLEVIATING HYPERANDROGENISM OF PCOS RATS THROUGH REGULATING PPARG1 AND HDAC3 EXPRESSION IN THE OVARIES

Characterization of Reproductive, Metabolic, and Endocrine Features of Polycystic Ovary Syndrome in Female Hyperandrogenic Mouse Models

Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis

Increased Expression of P450scc and CYP17 in Development of Endogenous Hyperandrogenism in a Rat Model of PCOS

Effects of Invigorating Spleen and Removing Phlegm Decoction on Insulin Resistance and Serum Adipokine Levels in PCOS Rats